Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin

Upsala Journal of Medical Sciences

Volumn 117, Issue 4, 2012, Pages 390-398

  Zhong, Yucheng ^a   Tang, Hongxia ^b   Zeng, Qiutang ^a   Wang, Xiang ^a   Yi, Guiwen ^a   Meng, Kai ^a   Mao, Yi ^a   Mao, Xiaobo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Children's Hospital   (China)

Author keywords

Cholesterol content; Coronary artery disease; Erythrocyte membranes; Rosuvastatin

Indexed keywords

CHOLESTEROL; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; CASE-CONTROL STUDIES; CHOLESTEROL; CORONARY ARTERY DISEASE; ERYTHROCYTE MEMBRANE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES;

EID: 84868227495     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2012.672345     Document Type: Article

References (31)

1. .Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol. 2007;49:2081-9.
2. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest. 2002;110:905-11.
3. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta. 2000;1529:164-74.
4. Guyton JR, Klemp KF. Development of the lipid rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol. 1996; 16:4-11.
5. Arbustini E, Morbini P, D'Armini AM, Repetto A, Minzioni G, Piovella F, et al. Plaque composition in plexogenic and thromboembolic pulmonary hypertension: the critical role of thrombotic material in pultaceous core formation. Heart. 2002;88:177-82.
6. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316-25.
7. Arbustini E. Total erythrocyte membrane cholesterol: an innocent new marker or an active player in acute coronary syndromes? J Am Coll Cardiol. 2007;49:2090-2.
8. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Chatzikyriakou SV, Mitrousi K, et al. Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease. Coron Artery Dis. 2008;19:583-90.
9. Giannoglou GD, Koskinas KC, Tziakas DN, Ziakas AG, Antoniadis AP, Tentes IK, et al. Total cholesterol content of erythrocyte membranes and coronary atherosclerosis: an intravascular ultrasound pilot study. Angiology. 2009;60: 676-82.
10. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Thomaidi A, Chatzikyriakou S, et al. Statin use is associated with a significant reduction in cholesterol content of erythrocyte membranes: a novel pleiotropic effect? Cardiovasc Drugs Ther. 2009;23:471-80.
11. Tziakas DN, Chalikias GK, Stakos D, Tentes IK, Papazoglou D, Thomaidi A, et al. Independent and additive predictive value of total cholesterol content of erythrocyte membranes with regard to coronary artery disease clinical presentation. Int J Cardiol. 2010;150:22-7.
12. Yu MM, Xu Y, Zhang JH, Wang CH, Wang XC, Cheng ZP, et al. Total cholesterol content of erythrocyte membrane levels are associated with the presence of acute coronary syndrome and high-sensitivity C-reactive protein. Int J Cardiol. 2010;145:57-8.
13. Zhang J, Pan L, Xu Y, Wu C, Wang C, Cheng Z, et al. Total cholesterol content of erythrocyte membranes in acute coronary syndrome: correlation with apolipoprotein A-I and lipoprotein (a). Coron Artery Dis. 2011;22:145-52.
14. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116:2634-53.
15. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001; 38:2114-30.
16. Braunwald E. Unstable angina. A classification. Circulation. 1989;80:410-14.
17. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Task Force on theManagement of Stable Angina Pectoris of theEuropeanSociety ofCardiology;ESCCommittee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: theTask Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-81.
18. ̧Sentürk T, Tütüncü A, Özdemir B, Ozdabakoglu O, Aydin S, Baran I, et al. Serum choline levels in patients with stable angina and acute coronary syndromes: relation to the severity of coronary artery disease. Coron Artery Dis. 2010;21: 466-71.
19. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
20. Berkelman T, Lagarias JC. Calcium transport in the green alga Mesotaenium caldariorum: preliminary characterization and subcellular distribution. Plant Physiol. 1990;93:748-57.
21. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
22. Kolodgie FD, Burke AP, Nakazawa G, Cheng Q, Xu X, Virmani R. Free cholesterol in atherosclerotic plaques: where does it come from? Curr Opin Lipidol. 2007;18:500-7.
23. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-18.
24. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934-40.
25. Lin HL, Xu XS, Lu HX, Zhang L, Li CJ, Tang MX, et al. Pathological mechanisms and dose dependency of erythrocyte-induced vulnerability of atherosclerotic plaques. J Mol Cell Cardiol. 2007;43:272-80.
26. Tziakas DN, Chalikias GK, Stakos D, Boudoulas H. The role of red blood cells in the progression and instability of atherosclerotic plaque. Int J Cardiol. 2010;142:2-7.
27. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. Creactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 2002;39:632-7.
28. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401-8.
29. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J. 2000;21:1000-8.
30. Sawabe M, Tanaka N, Nakahara K, Hamamatsu A, Chida K, Arai T, et al. High lipoprotein (a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart. 2009;95:1997-2002.
31. Spence JD. The role of lipoprotein(a) in the formation of arterial plaques, stenoses and occlusions. Can J Cardiol. 2010; 26(Suppl A):37A-40A.